Document:

Document

Exhibit 10.25

BioMe Biospecimen and Data Access Agreement
Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed.
This BioMe Biospecimen and Data Access Agreement (“Agreement”) is made by and between Icahn School of Medicine at Mount Sinai, a New York nonprofit education corporation, with a place of business at One Gustave L. Levy Place, New York, NY 10029 (“ISMMS”) and Mount Sinai Genomics, Inc., d/b/a Sema4, a Delaware corporation having a business address at 333 Ludlow St., South Tower, 3rd Floor, Stamford, CT 06902 (“Sema4”).
WHEREAS, ISMMS desires to support and to conduct research to further the educational, scholarship and research objectives of ISMMS as a nonprofit, tax-exempt educational institution;
WHEREAS, Sema4 desires to conduct research in order to support its R&D Activities (as defined below);
WHEREAS, ISMMS is willing to provide certain [***] for use by the parties in [***] under the terms specified herein;
WHEREAS, Sema4 is willing to conduct [***] provided by ISMMS and to provide such [***] to ISMMS for use by the parties in [***] under the terms specified herein; and
WHEREAS, Sema4 is a CLIA certified lab and has received and maintains approval from the New York State Department of Health to perform clinical whole exome sequencing in the manner set forth in Exhibit D hereto.
NOW, THEREFORE, in consideration of the mutual promises and covenants herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:
1.    DEFINITIONS. Capitalized terms not otherwise defined in this Agreement shall have the following meanings:
1.1    “Approved Protocol” means the applicable research protocol that has been approved by [***].
1.2    “BioMe Subjects” means those [***] in the BioMe Biobank.
1.3    “BioMe Biobank” is the [***] maintained by ISMMS that contains the Biospecimens.
1.4    “Biospecimens” means [***] collected from BioMe Subjects.
1.5    “Clinical Data” means, collectively, [***].
1.6    “Collaboration Agreement” means and agreement between a Collaborator or Subcontractor, on the one hand, and ISMMS or Sema4, on the other hand, that involves the Data.
1.7    “Collaborators” means ISMMS Collaborators (as defined in Section 4.8(b)) and/or Sema4 Collaborators (as defined in Section 6.9).
1.8    “Commercial Entity” means any entity other than a Non-Commercial Entity.
1.9    “Data” means, collectively, [***].
1

1.10    “Data Freeze” means the [***] to be made available to ISMMS under this Agreement and Exhibit D, attached hereto and incorporated herein by reference.
1.11    “De-Identified” (including its variants such as “De-Identify” and “De-Identification”) means [***].
1.12    “HIPAA” means the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and the implementing regulations, including, but not limited to, 45 C.F.R. Parts 160 and Part 164, all as may be amended from time to time.
1.13    “Institutional Review Board” or “IRB” means ISMMS’s institutional review board.
1.14    “Intellectual Property” means any and all rights in and to formulae, inventions, discoveries, technology, know-how, data, databases, documentation, reports, materials, writings, designs, computer software, algorithms, processes, principles, methods, techniques and other information, including patents, trademarks, service marks, trade names, registered designs, design rights, copyrights and any rights or property similar to any of the foregoing in any part of the world, whether registered, or not, together with the right to apply for the registration of any such rights.
1.15    “Non-Commercial Entity” means an entity that is a nonprofit organization, academic institution, government organization, or similar non-commercial entity.
1.16    “Protected Health Information” or “PHI” shall have the meaning of that term as defined in HIPAA.
1.17    “R&D Activities” means research, including for the discovery of clinical and commercial research tools, products (including components of products), therapies or services for the treatment, prevention, palliation, delay and/or diagnosis of diseases or disorders or the improvement of quality of life.
1.18    “Secure Access Portal” means, with respect to a party providing Data or making Data available to any third party recipient, a method of providing access to such Data to such recipient in a manner designed to ensure that Data remains on the servers or cloud-based service controlled by such party, for which functionality is enabled that is designed to prevent downloading by a third party, and where access is not permitted without appropriate authorization from the providing party or administrators authorized by the providing party. For purposes of this definition, servers or cloud-based services will be deemed to be controlled by a party if: (a) such servers or service are either owned, leased or otherwise contracted for by such party and (b) such party has the ability to administrate access and security controls for such servers or services.
1.19    “Secure File Transfer” means with respect to a party providing Data or making Data available to Collaborators including Subcontractors, a method of providing access to such Data by transferring Data. A Secure File Transfer is only permitted in those circumstances where access through a Secure Access Portal is not adequate to enable the conduct of the R&D Activities. A Secure File Transfer must be pursuant to a written Collaboration Agreement. The written Collaboration Agreement must set forth all of the terms and conditions contained in 6.9 and otherwise comply with the terms of this agreement.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	2

1.20    “Sequence Data” means, collectively, the [***] and the [***], conducted by Sema4 or its subcontractors as set forth in Exhibit D. Sequence Data excludes [***].
1.21    “Sequencing” includes [***] as set forth in Exhibit D, and any other methods set forth in the Approved Protocol or otherwise mutually agreed to by the parties.
1.22    “Subcontractors” include a person or entity that provides services to a party for purposes of performing a party’s obligations under this Agreement.
2.    APPROVED PROTOCOL. The parties agree to comply with all requirements of the Approved Protocol. In the event of a conflict or inconsistency between the terms of the Approved Protocol and the terms of this Agreement, the parties will work together to resolve the inconsistency in a manner consistent with the intention of this Agreement.
3.    BIOSPECIMENS.
3.1    ISMMS PROVISION OF BIOSPECIMENS TO SEMA4. ISMMS will provide Sema4 with [***] Biospecimens in accordance with the requirements set forth in Exhibit F and will use reasonable efforts to provide such Biospecimens within the timeframes set forth in Exhibit E, attached hereto and incorporated herein by reference. ISMMS will code each Biospecimen so that ISMMS may link it to Clinical Data concerning the BioMe Subject for such Biospecimen.
3.2    [Reserved.]
3.3    QUALITY APPROVAL. The acceptance criteria for Biospecimens are set forth in Exhibit F.
3.4    USE OF BIOSPECIMENS. Sema4 may use the Biospecimens only to perform [***] as set forth in the Approved Protocol and for Validation Purposes (as defined in Section 10.4(a)) in accordance with this Agreement. Sema4 may not use the Biospecimens for [***]. For clarity, Sequencing will be limited to those methods as set forth in the Approved Protocol or as otherwise mutually agreed by the parties.
3.5    LICENSE TO BIOSPECIMENS. ISMMS hereby grants to Sema4 a non-exclusive, worldwide, royalty free, fully paid-up, sublicensable (only to Subcontractors) license to [***] as set forth in the Approved Protocol and for Validation Purposes (as defined in Section 10.4(a)) in accordance with this Agreement.
3.6    DESTRUCTION UPON WITHDRAWAL OF PARTICIPATION IN BIOME BIOBANK. Sema4 will promptly destroy any Biospecimen for a BioMe Subject upon receipt of notice from ISMMS that such individual has withdrawn participation in the BioMe Biobank.
4.    SEQUENCING AND SEQUENCE DATA
4.1    SEQUENCING. Sema4 shall use [***] to complete the [***] Sequencing of all Biospecimens within [***] months from the date that ISMMS provides all of the Biospecimens to Sema4, as described in Exhibit E.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	3

4.2    ACCESS TO SEQUENCE DATA BY ISMMS. The Sequence Data shall be made available to ISMMS for download to ISMMS local systems as described in this Section 4.2 and in accordance with Exhibit D.
(a)    PROVISION OF [***] SEQUENCE DATA. Sema4 shall provide to ISMMS the [***] Data in the form set forth in Exhibit D. Sema4 shall use [***]  to provide ISMMS with the [***] Data within the timeframes set forth in Exhibit E. Sema4 shall make such [***] available to ISMMS within [***] days of completing [***].
(b)    PROVISION OF [***] DATA. Sema4 shall provide to ISMMS the [***] Data in the form set forth in Exhibit D. Sema4 shall use [***] to provide to ISMMS such [***] within the timeframes set forth in Exhibit E. Sema4 shall make such [***] available to ISMMS within [***] days of completing such [***].
(c)    CODING OF SEQUENCE DATA. Sema4 shall provide the Sequence Data to ISMMS for each Biospecimen with the original ISMMS bar code number associated with that Biospecimen.
(d)    TIME PERIOD OF ACCESS. After the [***] period immediately following ISMMS’s receipt of the [***], Sema4 shall [***] ISMMS with [***] to such [***].
4.3    QUALITY. Sema4 shall provide the same Sequence Data to ISMMS as Sema4 uses for its own R&D Activities.
4.4    [***]. This Agreement is [***] and ISMMS [***] any Biospecimens in the BioMe biobank.
4.5    SECURITY OF SEQUENCE DATA. Sema4 and ISMMS shall secure Sequence Data according to Section 6.4.
4.6    PROVISION OF ACCESS TO SEQUENCE DATA TO THIRD PARTIES. Sema4 may provide access to Sequence Data to third parties only as permitted by Section 6.9.
4.7    PROVISION OF SEQUENCE DATA TO JOURNALS. Sema4 and ISMMS may release Sequence Data as necessary to validate research findings as required by journals for publication or for non-profit or governmental funding agencies; provided, however, that a party shall provide [***] of Sequence Data [***] for that purpose.
4.8    ISMMS USE OF SEQUENCE DATA.
(a)    Subject to the terms and conditions of this Agreement, Sema4 hereby grants to ISMMS a nonexclusive, worldwide, royalty free, fully paid-up, sublicensable (only to Subcontractors and ISMMS Collaborators in accordance with Section 6.9) license to access, store and use the Sequence Data for research purposes described in Section 4.8(b). The license shall be perpetual except as set forth in Section 10.4(b).
(b)    ISMMS may use Sequence Data only for: (i) its own internal research purposes, and (ii) research conducted in collaboration with other Non-Commercial Entities (“ISMMS Collaborators”). ISMMS may not use Sequence Data in research collaborations with Commercial Entities or in any research sponsored or paid for 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	4

by any Commercial Entity, except as approved in advance in writing by Sema4, which may be withheld in Sema4’s sole discretion. This section does not apply to Analyses, as defined in Section 8 of this Agreement.
(c)    The restrictions set forth in Section 4.8(b) above shall expire: (i) for Sequence Data generated in the period of time between the Effective Date and [***] thereafter, [***]) years following the end of such [***] year period, and (ii) for Sequence Data generated in the subsequent one (1) year periods during the Term that follow such [***] year period, [***] years following the end of such subsequent one (1) year period. For Clarity, upon such [***], ISMMS shall [***] research collaborations with Commercial Entities.
5.    CLINICAL DATA.
5.1    PROVISION OF CLINICAL DATA. ISMMS shall provide to Sema4 Clinical Data associated with each Biospecimen as described in Exhibit C, attached hereto and incorporated herein by reference, and ISMMS shall use [***] to provide such Clinical Data within the timeframes set forth in Exhibit E.
(a)    DATA SCHEMA. The provisional data dictionary and data schema describing the content and format of the Clinical Data (“Data Schema”) to be provided to Sema4 are set forth as Exhibit C and incorporated herein by reference. ISMMS shall [***] Sema4; provided that, ISMMS [***] (e.g., t[***]). ISMMS [***] Clinical Data that ISMMS [***] and that ISMMS [***] the Data Schema, upon mutual agreement of the parties that ISMMS will [***] Data Schema, ISMMS shall [***] Sema4 [***] Clinical Data, and Exhibit C shall be automatically amended to reflect such mutual agreement. ISMMS shall [***] with Sema4 in providing the Clinical Data in a format that is usable by Sema4 and shall provide Clinical Data to Sema4 with [***] by Sema4 that [***], as mutually agreed by the parties, to [***] the Clinical Data by Sema4.
(b)    PROVISION OF KEY TO CODED CLINICAL DATA. With respect to the [***] Sequence Data, ISMMS will [***] in the [***] to the corresponding Clinical Data concurrently with the provision of the [***] to ISMMS.
5.2    SEMA4 LICENSE TO CLINICAL DATA. ISMMS hereby grants to Sema4 a nonexclusive, worldwide, royalty free, fully paid-up, sublicensable (only to Subcontractors of Sema4 and Sema4 Collaborators in accordance with Section 6.9) license to the Clinical Data to use such Clinical Data as permitted by this Agreement and the Approved Protocol (including for R&D Activities permitted under the Approved Protocol). The license shall be perpetual except as set forth in Section 10.4.
5.3    SECURITY OF CLINICAL DATA. Sema4 shall [***] that its Collaborators [***] Clinical Data as provided in Section 6.4.
5.4    PROVISION OF ACCESS TO CLINICAL DATA TO THIRD PARTIES. Sema4 may provide access to Clinical Data to third parties only as permitted by Section 6.9.
5.5    ISMMS USE OF CLINICAL DATA. For clarity, nothing herein shall be interpreted as restricting any legal use by ISMMS of Clinical Data.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	5

6.    DATA SECURITY, DATA PRIVACY AND DATA SHARING.
6.1    DE-IDENTIFICATION. ISMMS will only provide De-Identified Clinical Data to Sema4 under this Agreement. The Clinical Data shall be fully De-Identified by ISMMS under the HIPAA regulations. ISMMS shall use the HIPAA “safe harbor” method (45 CFR §164.514(b)(2)) for De-Identifying the Clinical Data provided to Sema4, unless the HIPAA “expert determination” method (45 CFR §164.514(b)(1)) is requested by Sema4 and mutually agreed to by the parties. If the “expert determination” method is used, Sema4 shall be [***]. If, despite ISMMS’s obligation to provide De-Identified Clinical Data to Sema4 under this Section 6.1, ISMMS [***], then ISMMS shall [***], and will provide [***]. In that case, ISMMS shall, within [***], fully De-Identify such Clinical Data and provide it to Sema4, either by: (a) [***], or (b) [***] the Data Schema. If Sema4 must [***] Clinical Data under this Section 6.1, ISMMS shall corresponding to such Clinical Data [***] that ISMMS provides Clinical Data that meets the definition of De-Identified Clinical Data.
6.2    NO RE-IDENTIFICATION. Except as specifically permitted by ISMMS and any necessary BioMe Subject consent, Sema4 shall not attempt in any manner, directly or indirectly, to identify the BioMe Subjects or their family members, or to enable any third party to do so, and shall not contact any BioMe Subject if identified for any reason. Sema4 shall notify ISMMS immediately if Sema4 identifies a BioMe Subject, or if it becomes aware that a Subcontractor or Sema4 Collaborator has identified such an individual. Sema4 agrees to destroy any remaining Biospecimens, Sequence Data or Clinical Data related to a BioMe Subject who has been so identified.
6.3    [***]. Sema4 will not use Clinical Data to [***], in a manner that [***], nor will Sema4 use the Clinical Data in a manner that may have [***].
6.4    SECURITY REQUIREMENTS. Sema4, with respect to Sequence Data and Clinical Data and ISMMS, with respect to Sequence Data, shall implement the security requirements set forth in Exhibit B attached hereto and incorporated by reference. Each party may provide access to Subcontractors or Collaborators to Sequence Data or Clinical Data as applicable, only as permitted by this Agreement and only through a Secure Access Portal, or pursuant to a Secure File Transfer, and in conformance with the Security Program defined at Exhibit B.
6.5    NOTIFICATION OF [***] NOT IN COMPLIANCE WITH AGREEMENT. A party shall report to the other party as soon as reasonably practicable, but in no event more than [***], after becoming aware of any [***] by the first party, its Collaborators or its Subcontractors, which [***] is in violation of this Agreement or applicable law. The notifying party shall promptly mitigate, to the extent practicable, any harmful effect of a [***] in violation of this Agreement or applicable law. Each party agrees to fully cooperate, coordinate with and assist the other parties in any investigation and in gathering the information necessary to determine any legal obligations.
6.6    APPLICABLE LAW. Each party shall, and shall ensure that its Collaborators and Subcontractors, use the Data only in accordance with applicable law, including but not limited to any applicable state health information confidentiality laws, and subject to any applicable restrictions or limitations described in the Approved Protocol.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	6

6.7    SITE OF ACTIVITIES. Each party shall perform all activities set forth in this Agreement within the United States. The Biospecimens and Data shall at all times remain within the United States.
6.8    SUBPOENAS AND COURT ORDERS. Sema4 shall notify ISMMS in the event Sema4 receives a subpoena or a court order to [***], with advance notice to allow ISMMS a reasonable time to object to the [***], if and to the extent such advance notice is legally permissible. ISMMS shall notify Sema4 in the event ISMMS receives a subpoena or a court order to [***], with advance notice to allow Sema4 a reasonable time to object to the [***], if and to the extent such advance notice is legally permissible.
6.9    DATA SHARING LIMITATIONS.
(a)    Sema4 may provide access to Clinical Data or Sequence Data to Subcontractors and to third parties under contract with Sema4 to access the Data for R&D Activities permitted under the Approved Protocol (such third parties collectively referred to herein as “Sema4 Collaborators”) pursuant to a written Collaboration Agreement, provided that, in addition to its obligations under Section 6.4, Sema4 shall:
(i)    grant access to Sema4 Collaborators and Subcontractors only [***];
(ii)    contractually prohibit Sema4 Collaborators and Subcontractors from [***];
(iii)    require Sema4 Collaborators and Subcontractors to: (1) not attempt in any manner, directly or indirectly, to [***], (2) not contact any [***], (3) notify Sema4 immediately if [***] in connection with the use of the Data by the Sema4 Collaborator or Subcontractor;
(iv)    prohibit Sema4 Collaborators and Subcontractors from using Clinical Data: (1) to [***], or (2) in a manner that [***].
(v)    require Sema4 Collaborators and Subcontractors to use the Data only in accordance with applicable laws, including but not limited to applicable state health information confidentiality laws;
(vi)    require Sema4 Collaborators and Subcontractors to use Data only for [***];
(vii)    require Subcontractors to use Data only to provide services to Sema4;
(viii)    require Sema4 Collaborators and Subcontractors to comply with the rules Sema4 issues to implement its Security Program as set forth in Exhibit B;
(ix)    require Sema4 Collaborators and Subcontractors to report to Sema4 as soon as reasonably practicable, but in no event more than [***], after becoming aware of any [***] that is in violation of this Agreement or applicable law, including [***] in violation of the requirements described in clauses (ii)-(viii) of this Section 6.9(a) and, within ten (10) business days of such notification, to submit to Sema4 a detailed written report including the date and nature of the event, actions taken or to be taken to remediate the issue(s) and plans or processes developed to prevent 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	7

further [***], including specific information on timelines anticipated for action; and
(x)    require Sema4 Collaborators and Subcontractors to [***] and confirm to Sema4 in writing the [***] immediately upon the expiration or termination of the Collaboration Agreement; and
(xi)    be fully responsible to ISMMS under Section 14.2 of this Agreement for compliance by Sema4 Subcontractors and Sema4 Collaborators with the requirements described this Section 6.9(a).
(b)    ISMMS may provide access to Sequence Data to its Subcontractors and to ISMMS Collaborators (as defined above in Section 4.8(b)) pursuant to a written Collaboration Agreement, provided that ISMMS shall:
(i)    grant access to ISMMS Collaborators and Subcontractors only through a [***];
(ii)    contractually prohibit ISMMS Collaborators and Subcontractors from [***];
(iii)    require ISMMS Collaborators and Subcontractors to use Sequence Data only in accordance with applicable laws, including but not limited to applicable state health information confidentiality laws;
(iv)    require ISMMS Collaborators to use Sequence Data only for [***];
(v)    require Subcontractors to use Sequence Data only [***];
(vi)    ensure that ISMMS Collaborators and Subcontractors shall report to ISMMS as soon as reasonably practicable, but in no event more than [***], after becoming aware of any [***] in violation of this Agreement or applicable law, including [***] in violation of the requirements described in Section 6.9(b) and, within ten (10) business days of such notification, to submit to ISMMS a detailed written report including the date and nature of the event, actions taken or to be taken to remediate the issue(s) and plans or processes developed to prevent further such [***], including specific information on timelines anticipated for action;
(vii)    require ISMMS Collaborators and Subcontractors to comply with the rules ISMMS issues to implement its Security Program at Exhibit B; and
(viii)    require ISMMS Collaborators and Subcontractors to [***], or to [***] immediately upon the expiration or termination of the Collaboration Agreement; and
(ix)    be fully responsible to Sema4 under Section 14.3 of this Agreement for compliance by such Subcontractors and ISMMS Collaborators with the requirements described in this Section 6.9.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	8

7.    CONFIDENTIALITY.
7.1    DEFINITION. For the purposes of this Agreement, “Confidential Information” means any proprietary and confidential information, including but not limited to software and data (including financial, operational, customer, and vendor data owned or controlled by one party hereto, and disclosed by such party to the other during the Term in connection with this Agreement) where such information is not generally known by or disclosed to the public, and shall include, without limitation, the terms of this Agreement. Notwithstanding anything herein to the contrary, “Confidential Information” shall not include information that is: (a) already known to or otherwise in the possession of the party receiving such information hereunder prior to receipt from the other party and that was not known or received as the result of violation of any obligation of confidentiality to the disclosing party; (b) publicly available or otherwise in the public domain prior to disclosure by a party hereto; (c) rightfully obtained by a party hereto from any third party who imposes no confidentiality obligation thereon and who the receiving party does not know to be in breach of any confidentiality obligation to the disclosing party; or (d) developed by a party without use of or reference to (i.e. independently of) any disclosure of Confidential Information made by the other party hereunder, as demonstrated by written or electronic records. Confidential Information shall not include Clinical Data, Sequence Data and/or Analyses (as defined in Section 8). Confidential Information includes the terms and conditions of this Agreement.
7.2    OBLIGATION. Each party (as a “Receiving Party”) shall maintain all of the Confidential Information of the other party (the “Disclosing Party”) in strict confidence and shall protect such information with the same degree of care that the Receiving Party exercises with its own Confidential Information, but in no event less than a reasonable degree of care. Except as provided in this Agreement, a Receiving Party shall not use or disclose any Confidential Information of the Disclosing Party without the express prior written consent of the Disclosing Party; provided that access to and use of any of the Disclosing Party’s Confidential Information may be made to (i) those employees, faculty and other representatives within a Receiving Party's organization who have been informed of the confidentiality obligations and use restrictions herein, provided such employees, faculty and other representatives have a need to use the information to perform the Receiving Party's obligations under this Agreement (ii) a Receiving Party’s Collaborators and Subcontractors in each case after the applicable Collaborator or Subcontractor has executed a legally binding non-disclosure or confidentiality agreement with provisions no less stringent than those applicable to the Receiving Party under this Agreement, (iii) a Receiving Party’s counsel, accountants and other professional advisors, and (iv) the financial advisors and actual or potential financing sources or investors of a Receiving Party in each case after the applicable financial advisor or actual or potential financing source or investor has executed a legally binding non-disclosure or confidentiality agreement with provisions no less stringent than those applicable to the Receiving Party under this Agreement (collectively, a Receiving Party’s “Individual Recipients”). In addition, a party receiving Confidential Information hereunder may disclose it pursuant to the order or requirement of a court or governmental agency or administrative body of competent jurisdiction, provided that the party receiving such order shall (a) notify the other party promptly of such required disclosure (and prior to the deadline for such required disclosure to the extent reasonably practical), (b) cooperate at the Disclosing Party’s written request and expense, with the Disclosing Party’s efforts to legally contest, 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	9

request confidential treatment of, limit the scope of, or otherwise avoid or minimize such required disclosure and (c) shall disclose Confidential Information only to the extent required pursuant to the applicable order or requirement. Each party as a Receiving Party shall be fully responsible to the other party hereto for compliance by its Individual Recipients with all of the confidentiality obligations and use restrictions herein.
7.3    RETURN OF CONFIDENTIAL INFORMATION. All of a Disclosing Party's Confidential Information, and all copies thereof, shall be and remain the property of the Disclosing Party. All such Confidential Information and any and all copies and reproductions thereof shall, upon the sooner of fifteen (15) days after (a) the receipt of written request of the Disclosing Party or (b) the expiration or termination of this Agreement, be promptly returned to the Disclosing Party or destroyed (and such destruction confirmed in writing provided to the Disclosing Party) at the Disclosing Party's directio; provided that (i) during the term of any license hereunder a Receiving Party shall not be obligated to return or destroy any licensed information; (ii) in no event shall Analyses be required to be returned or destroyed and (iii) this Agreement need not be returned or destroyed.
8.    ANALYSES. Neither party is providing analysis of any Data under this Agreement to the other party (except the annotations to the Sequence Data as described in Exhibit D). Any analysis, resulting metadata created from such analysis, research results and/or conclusions resulting from research or R&D Activities using the Data, including but not limited to the discovery of a therapeutic or diagnostic target, or therapeutic or diagnostic strategy (collectively, “Analyses”) is outside the scope of this Agreement and shall be owned by the party who created it. Each party is free to commercialize its Analyses, in collaboration with any other parties it may choose, with the exception that such party shall not use Analyses (or any information or data whatsoever) to identify any individual BioMe Subject (and shall not permit a third party to do so).
9.    COMPENSATION.
9.1    LICENSE OR USE FEE. Neither party shall charge the other party any license or use fee for the materials and Data provided pursuant to this Agreement. Reagents and materials for the preparation and shipment of the Biospecimens may be provided by Sema4 as specified in the Approved Protocol.
9.2    [***] FEE. Sema4 shall [***]ISMMS $[***] for ISMMS’s [***] mutually agreed upon or otherwise specified in this Agreement (“[***]”). The [***] but is being provided only as [***] for the [***] associated with the [***] of Biospecimens and for [***]. If more than [***] samples are provided an [***]will imposed that is comparable to the [***].
9.3    INVOICES. ISMMS shall generate an invoice to Sema4 for the [***] Fee, as applicable, and Sema4 shall pay the invoice within  [***].
9.4    NO INDUCEMENT. No part of any consideration paid hereunder is a prohibited payment for recommending or arranging for the referral of business or the ordering of items or services. Additionally, the parties agree that neither this Agreement nor any consideration paid hereunder is contingent upon ISMMS’s use, recommendation or purchase of any products or services of Sema4 or any of their affiliates.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	10

10.    TERM AND TERMINATION.
10.1    TERM. The term of this Agreement (the “Term”) shall begin on the date on which the Agreement is signed by all parties (the “Effective Date”) and shall continue for five (5) years, unless terminated earlier pursuant to this Section 10. This Agreement shall automatically terminate at the end of the initial five(5) year term, unless an extension or renewal is mutually agreed to in writing signed by each party’s authorized representative.
10.2    TERMINATION. A party may terminate this Agreement without penalty to the terminating party, for the following reasons:
(a)    Material breach of the Agreement, if the breaching party fails to cure the breach to the satisfaction of the non-breaching parties, within [***] calendar days of breaching party’s receipt of a written notice of the breach; provided that, if the occurrence of a material breach is subject to a good-faith dispute, then the party purporting to terminate this Agreement or seek remedies in Section 10.8 for such material breach shall not have the right to do so until the matter is finally adjudicated or otherwise settled by the parties;
(b)    Pursuant to Sections 13.5, 16.5 and 16.12.
(c)    If another party: (i) becomes insolvent; makes a transfer in fraud of creditors; makes an assignment for the benefit of creditors; or admits, in writing, its inability to pay its debts as they become due; (ii) commits an act of bankruptcy; files a petition under the United States Bankruptcy Code or under any other similar federal or state law; is adjudged bankrupt; or is named in a pleading or motion filed in any court proposing to reorganize or adjudicate as a bankrupt, and that pleading or motion is not discharged or denied within [***] days after its filing; (iii) has a receiver or trustee appointed for all or substantially all of its assets, and the receiver or trustee is not discharged within [***] days after its appointment; (iv) has filed against it any tax lien respecting all or substantially all of its property and such tax lien shall not be discharged, removed, or bonded over within [***] days of the date on which it was filed; or (v) has its assets assigned by law;
(d)    Immediately upon written notice if another party is convicted in a criminal proceeding for a violation of HIPAA, or if a court or administrative agency has determined that the party has violated any standard or requirement of HIPAA, or any other security or privacy laws; and
(e)    If, following the Effective Date of this Agreement, there is a change in federal or state laws, regulations or governmental administrative policy, or a change in any interpretation of such laws, rules, regulations, policies or general instructions regarding genetic or genomic research that: (i) causes a party to be unequivocally unable to fulfill its obligations in this Agreement, or (ii) renders Sema4 unable to use the Data for R&D Activities permitted by the Approved Protocol, then the parties shall negotiate in good faith to modify the Agreement to avoid any such statutory or regulatory violation in accordance with industry standards and this Agreement shall only terminate in the event that the parties are unable to reach an agreement within [***] days. Upon termination under this Section 10.2(e), 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	11

ISMMS shall return or destroy the Sequence Data, Sema4 shall return or destroy the Biospecimens, the Sequence Data and the Clinical Data.
10.3    TERMINATION BY SEMA4. Sema4 has the right, but not the obligation, to terminate this Agreement upon [***] days prior written notice if [***]% of Biospecimens [***] the [***].
10.4    EFFECT OF TERMINATION.
(a)    Upon termination or expiration of this Agreement, Sema4 shall [***] and shall cause any Sema4 Subcontractor to [***] Biospecimens. Sema4 shall [***] to ISMMS, except that Sema4 may [***] Biospecimens to [***]. For purposes of this Agreement, “[***]” means [***].
(b)    If this Agreement is terminated by Sema4 under Section 10.2(a) as a result of ISMMS’s breach of its obligations under Section 3.1, Section 3.3, Section 4.8(b) or Section 6 or under Section 10.3, then the [***], and in addition to any [***], ISMMS shall [***] the Sequence Data, with the [***] that ISMMS shall [***]. The termination of this Agreement for any other reason shall not affect the [***], but in the event of a termination of this Agreement under Section 10.2(a) as a result of ISMMS’s breach of its obligations under any provision of this Agreement other than Section 3.1 or Section 3.3, Sema4 shall have such other remedies as may be available to it at law or in equity.
(c)    If this Agreement is terminated by ISMMS under Section 10.2(a), then the [***]. In addition to any remedies available to ISMMS at law or in equity, Sema4 shall [***] the Clinical Data [***], with [***] that Sema4 shall [***] Clinical Data that was [***]. After termination, Sema4 [***], and may [***] Analyses, but Sema4 shall [***].
(d)    In the case of termination by ISMMS under Section 10.2(c), the [***] and Sema4 shall, automatically and without any further actions of the parties, [***] and Sema4 shall [***].
(e)    In the case of any termination or expiration of this Agreement, a party shall be permitted to retain and use Analyses conducted prior to the effective date of termination.
(f)    In the case of any termination by Sema4 under Section 10.3, Sema4 shall [***] ISMMS the Sequence Data that was generated prior to termination and ISMMS shall concurrently deliver to Sema4 the key to the code that associates Clinical Data with such Sequence Data. In addition, Sema4 will [***] and [***] ISMMS, except that Sema4 may [***] Biospecimens for which Sequence Data was [***], to [***] the Data that each party retains under this Section 10.4(f).
10.5    TREATMENT OF SEQUENCE DATA AND CLINICAL DATA IN THE EVENT OF LITIGATION. If litigation is brought against ISMMS by any BioMe Subjects seeking return or destruction of their Biospecimens, Sequence Data and/or Clinical Data, ISMMS shall provide prompt notice of the litigation to Sema4. ISMMS and Sema4 shall destroy any associated Biospecimens, Sequence Data and Clinical Data if ordered by a court to do so or if the parties to such litigation agree to do so in a manner consistent with law in settlement of the litigation. ISMMS shall not agree with any third-party to destroy 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	12

Sequence Data in Sema4 ‘s possession absent consultation with Sema4 and negotiation in good faith with Sema4’s participation to avoid such a settlement. Except to the extent expressly provided by a court order, Sema4 shall not be obligated to destroy (a) any of its Analyses obtained from, or performed using, Sequence Data or Clinical Data prior to return/destruction of such Data, and (b) any sample-level Clinical Data that was used to perform or obtain such Analyses.
10.6    INJUNCTION. The parties agree that any violation of this Agreement may cause irreparable harm to another party, for which money damages may not be sufficient. Accordingly, in addition to other remedies available to each party at law, in equity, or under this Agreement, in the event of any threatened or actual violation by another party of any provision of this Agreement, the first party shall be entitled to seek an injunction or other decree of specific performance with respect to such violation without the necessity of posting a bond or other security and without the necessity of demonstrating actual damages.
10.7    SURVIVAL; SPECIFIED REMEDIES. Rights and obligations which by their nature should survive, or which this Agreement expressly states shall survive, shall remain in full force and effect following termination or expiration of this Agreement. If Sema4 materially breaches its surviving obligations under Sections 4.5, 4.6, 5.3, 5.4 or 6 and fails to cure such breach within thirty (30) calendar days of its receipt of a written notice from ISMMS of such breach then [***]. In addition to any remedies available to ISMMS at law or in equity, Sema4 shall [***] Clinical Data remaining in their possession, with the exception that they shall not be required to [***] Clinical Data that was used to perform or obtain Analyses. After termination, Sema4 may utilize such Clinical Data solely to [***], and may use such [***], but shall not conduct any new research using such Clinical Data. If ISMMS materially breaches its surviving obligations under Sections 4.8(b) or 6 then the [***]. In addition to any damages at law or in equity, ISMMS shall [***] Sequence Data, with the exception that ISMMS shall not be required to [***] Sequence Data that was used to perform or obtain Analyses. After termination, ISMMS may utilize Sequence Data to [***], may provide Sequence Data to journals in accordance with Section 4.7, and may use Analyses, but ISMMS shall not conduct any new research using such Sequence Data. In the event the ISMMS material breach involves the disclosure or transfer of Sequence Data to a Commercial Entity, then ISMMS shall make reasonable efforts that such Commercial Entity [***] and that ISMMS and such Commercial Entity each [***] that resulted from such material breach.
11.    PUBLICITY. A party shall not use another’s logo, name or the name of any of another party’s trustees, officers, faculty members, students, employees, faculty, consultants, or representatives, or any adaptation of any of the foregoing, including in any publication, advertising, promotion, press release, or to suggest endorsement, without such other party’s prior written consent, which may be granted or denied in such party’s discretion. In the case of ISMMS, such consent shall be granted or denied by the Vice President, Office of Marketing and Communications of the Mount Sinai Health System.
12.    INTELLECTUAL PROPERTY.
12.1    PRE-EXISTING INTELLECTUAL PROPERTY. Ownership of Intellectual Property existing as of the Effective Date or developed or obtained outside of this Agreement is not affected by this Agreement, and no party shall have any claims to or rights in any 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	13

such pre-existing Intellectual Property of another party, except as may be otherwise expressly provided in any other written agreement between the parties.
12.2    NO JOINT INVENTIONS ARE ANTICIPATED BY THIS AGREEMENT. The parties may negotiate a separate agreement for the sharing of joint Intellectual Property in the event that the parties engage in any collaborative research between the parties that could result in joint inventions.
12.3    INTELLECTUAL PROPERTY CREATED UNDER THIS AGREEMENT. Unless otherwise agreed in writing, each party retains ownership of all Intellectual Property developed solely by it or its employees from the activities performed under this Agreement.
12.4    NO OTHER RIGHTS TO CLINICAL DATA OR BIOSPECIMENS. Except as specifically set forth herein, the access to and use of the Clinical Data, Sequence Data and Biospecimens under this Agreement do not imply, and shall not include, any license or transfer of data or Intellectual Property rights or ownership to the other party. Except as expressly set forth in this Agreement, Sema4 shall not give, transfer, license, sell or otherwise provide access to the Clinical Data and Biospecimens to any third party.
12.5    BIOSPECIMENS AND/OR CLINICAL DATA. ISMMS shall own the Biospecimens and Clinical Data at all times.
12.6    SEQUENCE DATA. Except as set forth in Section 10.4(d), Sema4 shall own the Sequence Data at all times.
13.    REPRESENTATIONS.
13.1    REPRESENTATIONS AND AGREEMENTS. ISMMS represents and agrees that: (a) in its collection, storage, processing and transfer of Biospecimens and Clinical Data, ISMMS has complied with and shall comply with all federal and state laws and regulations that are applicable to ISMMS; (b) ISMMS is permitted to provide Biospecimens and Clinical Data to Sema4 pursuant to the terms of a valid informed consent (“Informed Consent”) and HIPAA authorization (“HIPAA Authorization”) approved by an appropriate IRB and signed by the applicable subject from whom such Biospecimens and Clinical Data originated (the “Subject”) or the Subject’s legally authorized representative (unless such signature is waived by the IRB), which Informed Consent and HIPAA Authorization complies with federal and state laws applicable to ISMMS; (c) the Informed Consent and HIPAA Authorization are or shall be appropriately documented and permit or shall permit the activities contemplated by this Agreement, including the disclosure and use of the Subject’s Biospecimens and Clinical Data in accordance with this Agreement; (d) ISMMS has the right to provide the Biospecimens and Clinical Data to Sema4 for use in accordance with this Agreement and the Approved Protocol; (e) the Approved Protocol has been approved by the IRB; and (f) it is not a party to or bound by any arrangements, agreements or commitments with or to any third party that may limit Sema4’s rights to access or use the Biospecimens, Clinical Data, Sequence Data and/or Analyses in accordance with the provisions of this Agreement.
13.2    DISCLAIMER OF WARRANTIES. Except for the representation provided in Section 13.1 herein, THE CLINICAL DATA AND BIOSPECIMENS ARE PROVIDED BY 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	14

ISMMS “AS IS” AND ISMMS DISCLAIMS ANY WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO THE CLINICAL DATA AND BIOSPECIMENS, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY AS TO THE RESULTS OF ANY RESEARCH OR CLINICAL TRIAL. WITHOUT LIMITATION OF THE FOREGOING, ISMMS MAKES NO REPRESENTATION OR WARRANTY AS TO THE IDENTITY, PURITY, SAFETY, OR ACTIVITY OF THE BIOSPECIMENS. FURTHER, SEMA4 ACKNOWLEDGES THAT THE BIOSPECIMENS MAY HAVE UNKNOWN CHARACTERISTICS, MAY CARRY INFECTIOUS AGENTS, OR MAY OTHERWISE BE HAZARDOUS. SEMA4 AGREES TO TAKE APPROPRIATE PRECAUTIONS WHEN HANDLING BIOSPECIMENS AND SHALL ASSUME ALL RESPONSIBILITY FOR THE SAFE USE AND HANDLING OF BIOSPECIMENS BY SEMA4, ITS EMPLOYEES, AGENTS AND REPRESENTATIVES.
13.3    NO CLINICAL USE OF SEQUENCE DATA. ALL SEQUENCE DATA PROVIDED BY SEMA4 TO ISMMS IS PROVIDED FOR RESEARCH PURPOSES ONLY. Although Sema4 is a CLIA-certified lab and the parties anticipate the possible return of the Sequence Data findings to BioMe Subjects and/or the use Sequence Data in the treatment of BioMe Subjects, such uses are not addressed by this Agreement and will be subject to an approved IRB protocol and any and all applicable laws.
13.4    LIMITATION OF LIABILITY. NO PARTY SHALL BE LIABLE TO ANOTHER PARTY IN CONNECTION WITH THIS AGREEMENT FOR ANY INDIRECT, CONSEQUENTIAL, PUNITIVE, OR OTHER DAMAGES SUFFERED BY SUCH PARTY OR ANY OTHER PERSON, INCLUDING BUT NOT LIMITED TO THE LOSS OF, DELAY OF, OR FROM THE USE OF CLINICAL DATA BIOSPECIMENS AND/OR SEQUENCE DATA, OR FROM ANY ANALYSES BASED ON OR OBTAINED FROM THE CLINICAL DATA, BIOSPECIMENS AND/OR SEQUENCE DATA, EXCEPT TO THE EXTENT THAT DAMAGES OF SUCH NATURE ARE INCURRED BY A THIRD PARTY AND ARE INCLUDED WITHIN THE INDEMNIFIABLE CLAIMS FOR WHICH A PARTY IS RESPONSIBLE UNDER SECTION 14.1.
13.5    NO SUSPENSION, EXCLUSION, DEBARMENT, CIVIL MONETARY PENALTY OR CONVICTION. Both as a material condition to this Agreement and as a continuing representation during the Term of this Agreement, each party represents that neither it nor any of its owners, officers, directors, employees, nor any of its agents or Subcontractors providing services or otherwise undertaking activities under this Agreement, have been suspended, excluded, or debarred from any government payer program nor debarred pursuant to the Federal Food, Drug, and Cosmetic Act. A party shall immediately notify the other party in writing of any such suspension, exclusion or debarment, and such notified party has the right to terminate this Agreement immediately upon such notice.
13.6    COMPLIANCE WITH LAW. Each party shall fully comply with all applicable federal, state, and local laws and regulations in its performance of this Agreement.
14.    INDEMNIFICATION.
14.1    MUTUAL INDEMNIFICATION. Each party agrees to indemnify, hold harmless, and to have the first option to defend, another party and its affiliates and its and their employees, 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	15

employers, officers, directors, trustees, and agents, and, in the case of ISMMS, IRB or committee members (collectively, “Indemnitees”) from and against of any and all claims, lawsuits or actions (“Claims”) brought by any third party and any liabilities, damages, costs and expenses arising from any such Claim, including reasonable attorneys’ fees, (collectively, “Damages”) arising from: (a) [***] by such party; and/or (b) [***] of such party.
14.2    ADDITIONAL INDEMNIFICATION BY SEMA4. In addition to the indemnification above, Sema4 agrees to indemnify, defend, and hold harmless ISMMS Indemnitees from and against any and all Damages arising from any Claim resulting from [***] of Sema4 [***] to comply with the requirements of this agreement, including those described in [***].
14.3    ADDITIONAL INDEMNIFICATION BY ISMMS. In addition to the indemnification above, ISMMS agrees to indemnify, defend, and hold harmless the Indemnitees of Sema4 from and against any and all Damages arising from any Claim resulting from [***] to comply with the requirements described in [***].
14.4    LIMITATIONS. The indemnifying party’s obligations under this Section 14 do not apply to that portion of a Claim caused by the [***] of the Indemnitee or the Indemnitee’s [***], or by such Indemnitee’s or such Indemnitee’s [***] failure to comply with applicable law.
14.5    PROCEDURES. The party whose Indemnitees are subject to indemnification hereunder shall promptly notify the indemnifying party of any Claim and Damages; however, any failure by an Indemnitee to provide prompt notice shall not relieve the indemnifying party of its obligations hereunder except to the extent that the indemnifying party is prejudiced by such failure. Upon notice of a Claim, the indemnifying party, at its sole expense, shall provide counsel to diligently defend Indemnitee in, and shall have the right to control the defense of, the Claim, whether or not the Claim is rightfully brought or filed. The indemnified party and its Indemnitees shall cooperate, at the indemnifying party’s expense, in the defense or disposition of a Claim. An Indemnitee may engage its own defense counsel, at its own expense, to monitor the progress of the defense. An Indemnitee shall not settle a Claim without the indemnifying party’s prior written consent, which consent shall not be unreasonably withheld or delayed. The indemnifying party shall not compromise or settle a Claim without an Indemnitee’s prior written consent unless the settlement involves solely the payment of money for which the indemnifying party is solely liable. No settlement of a Claim by an indemnifying party shall be entered that includes an admission of fault or wrongdoing by any Indemnitee or that requires an Indemnitee to undertake a future course of action without that Indemnitee’s written consent to such components.
15.    INSURANCE. Each party agrees to maintain in force at its sole cost and expense, with reputable insurance companies having an AM Best rating of A-VII or better, or equivalent self-insurance, general liability insurance coverage in amounts equal to at least [***] per occurrence and [***] in the aggregate. Each party shall maintain this coverage for the duration of the Agreement, and if the policy is claims-made with unlimited tail coverage or until any applicable statute of limitations period has passed. Such policy shall cover liability assumed under contract for such party’s owns acts or omissions. Each party agrees to furnish the other party with a certificate of insurance indicating the required coverage upon request. Each party shall notify the other party 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	16

within thirty (30) days of any notice of cancellation or non-renewal of, or material change in, its insurance coverage. The failure to secure appropriate insurance in no way limits liability pursuant to this Agreement.
16.    MISCELLANEOUS.
16.1    NOTICE. Any notice required or permitted hereunder shall be in writing and shall be deemed given as of the date it is: (i) delivered by hand, (ii) received by registered or certified mail, postage prepaid, return receipt requested, or (iii) delivered by a nationally recognized express courier service, and addressed to the party to receive such notice at the addresses set forth further below.
If to ISMMS:
_______________________________
_________________________
____________________________
________________
Attn: _______________________________
with a copy for legal notices only to:
_____________________________
________________________________
___________________
Attn: _____________
If to Sema4
________
________________
________________
Attn: _____________
The parties may change its address by giving the other parties written notice, delivered in accordance with this Section 16.1.
16.2    GOVERNING LAW AND VENUE. This Agreement shall be construed, governed, and enforced in accordance with the laws of the State of New York, without giving effect to any principles of conflicts of laws. All actions arising out of this Agreement shall be brought in, and the parties hereby submit to the exclusive jurisdiction of and venue in, any state or federal courts located within the City of New York, State of New York.
16.3    ENTIRE AGREEMENT. This Agreement sets forth the entire agreement and understanding among the parties as to the subject matter of this Agreement and supersedes all prior documents, term sheets, verbal consents or understandings with regard to the subject matter of this Agreement.
16.4    MODIFICATION. No amendment, changes, extensions or modifications to this Agreement shall be valid and binding unless in writing and signed by the parties’ duly authorized individuals.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	17

16.5    SEVERABILITY. If any one or more provisions of this Agreement shall be found to be illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby, provided the surviving agreement materially comports with the parties’ original intent. If applicable, the parties shall promptly agree upon replacement provision(s) that approximate as closely as possible the spirit and intent of the invalid provision(s). In the event the parties are unable to agree to new or modified provisions as required to bring the entire Agreement into compliance, either party may terminate this Agreement on thirty (30) days’ written notice to the other party.
16.6    SIGNATURE AND COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be an original, and all such counterparts together shall constitute the entire Agreement. The parties agree that execution of this Agreement by exchanging facsimile, portable document format (.pdf), or other imaged signatures shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this Agreement, each party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such imaged signatures or maintenance of the executed agreement electronically.
16.7    ASSIGNMENT. No party may assign, transfer, delegate, or pledge this Agreement and/or any of its obligations hereunder to any third party without the prior written consent of the other party, provided that (i) during any period when ISMMS has the authority to elect a majority of the board of directors of Sema4, Sema4 shall have the right to assign this Agreement to any successor to all or substantially all of the business of Sema4 without any consent of ISMMS (other than such consent as is required by the certificate of incorporation or bylaws of Sema4), and (ii) during any period when ISMMS does not have the authority to elect a majority of the board of directors of Sema4, Sema4 shall have the right to assign this Agreement to any successor to all or substantially all of the business of Sema4 with the prior written consent of ISMMS which shall not be unreasonably withheld, conditioned or delayed. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties and their respective successors and permitted assigns.
16.8    INDEPENDENT CONTRACTORS. For purposes of this agreement, each party’s relationship with the other is and shall be considered to be that of an independent contractor, and no partnership, joint venture, co-venture, employer/employee, principal/agent, master/servant or other similar relationship is created, or intended to be created, hereby. No party is, nor shall be, the agent or employee of the other, and no party has authority to act on behalf of any other party or to bind the other party to any legal obligation vis-à-vis a third party, in any matter except to the extent expressly agreed upon in writing signed by both parties hereto.
16.9    THIRD PARTY BENEFICIARIES. Nothing contained in this Agreement shall be construed to create any rights or benefits in a third party, including, without limitation, research participants.
16.10    WAIVER. The delay or failure of either party to exercise any of its rights under this Agreement for a breach thereof shall not be deemed to be a waiver of such rights, nor shall the same be deemed to be a waiver of any subsequent breach, either of the same provision or otherwise.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	18

16.11    CUMULATIVE REMEDIES. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party shall be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy shall not preclude the exercise of any other remedy.
16.12    DISABILITY. If either party shall be prevented from the performance of any act required hereunder for any reason beyond such party’s reasonable control, including but not limited to, strike, lockouts, labor troubles, governmental or judicial actions or orders, riots, insurrections, terrorism, war, acts of God, extreme weather events, earthquake, epidemics, fire, embargoes, or other reason beyond the party’s control (a “Disability”), then such party’s performance shall be excused for the period of the Disability. The foregoing shall not be applicable to excuse (a) any obligation of such party to pay monies under this Agreement, or (b) any obligations of such party to indemnify the other party. The party affected by the Disability shall notify the other party of such Disability as provided for herein as soon as reasonably possible in light of the circumstances giving rise to such Disability. If the circumstances causing the delay or failure to perform continue for longer than thirty (30) business days, the other party shall be entitled to terminate this Agreement by notice to the other party in writing with immediate effect, and such termination shall not be considered termination for cause. With respect to Sema4, a Disability shall include the inability of Sema4 to obtain materials necessary to perform the Sequencing on commercially reasonable terms and within proposed timelines; but only to the extent Sema4 uses commercially reasonable efforts to avoid such Disability.
16.13    HEADINGS. The captions or headings in this Agreement are made for convenience and general reference only, and shall not be construed to describe, define or limit the scope or intent of the terms and conditions of this Agreement.
16.14    DISPUTE RESOLUTION. If a dispute arises between the parties concerning any right or duty under this Agreement, then the parties shall confer, as soon as practicable, in an attempt to resolve the dispute amicably. If the parties are unable to resolve the dispute amicably, the parties each hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts located in the County and State of New York.
[Signature Page Follows]
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	19

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives below.
															
	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI		MOUNT SINAI GENOMICS, INC.
					
					
					
	By:
	/s/ Erik Lium
		By:
	/s/ illegible

	Name 	Erik Lium		Name	
	Title:	Executive Vice President		Title:	
					
	Date:
	7/19/2019 | 5:41 PM EDT    
		Date:
	Date: 7/19/2019 | 5:55 PM EDT    

			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 

EXHIBIT A
[reserved]
			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 

EXHIBIT B
[***]
			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 

EXHIBIT C
DATA SCHEMA
[***]
			
	Legend:

	
	Date fields, to be date-shifted (see
algorithm)
	
	Visit/encounter key fields transformation or 
substitution
	
	Other key field transformation or 
substitution
	
	Non-key field transformation or
substitution
	
	Scan for possible PHI

			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 

EXHIBIT D
SEQUENCING METHODS AND DELIVERABLES
[***]
			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 

EXHIBIT E
BIOSPECIMEN AND DATA EXCHANGE REPRESENTATIVE TIMELINE
[***]
															
					
					
					
					
					
					
					

			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 

Exhibit F
BIOSPECIMEN ACCEPTANCE CRITERIA
[***]
			
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed.Document

Exhibit 10.26
CONFIDENTIAL

NON-EXCLUSIVE PATENT LICENSE AGREEMENT
between
Mount Sinai Genomics, Inc.
and
Icahn School of Medicine at Mount Sinai
________________________________________
Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed.

CONFIDENTIAL

TABLE OF CONTENTS
												
				Page
				
	1.		DEFINITIONS
	1
				
	2.		LICENSE GRANT
	5
				
	3.		FEES, ROYALTIES, AND PAYMENTS
	6
				
	4.		REPORTS AND PAYMENTS
	7
				
	5.		CONFIDENTIALITY; PUBLICITY; USE OF NAME
	10

				
	6.		PATENT MATTERS
	11
				
	7.		REPRESENTATIONS; DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITIES
	11
				
	8.		INDEMNIFICATION
	13
				
	9.		INSURANCE
	14

				
	10.		TERM AND TERMINATION
	14
				
	11.		EFFECT OF TERMINATION
	15
				
	12.		ADDITIONAL PROVISIONS
	15

						
	Exhibit A:	Licensed Patents
	Exhibit B:	Form of Quarterly Royalty Report
	Exhibit C:	Calculation of Running Royalties

						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	i

CONFIDENTIAL

Non-Exclusive Patent License Agreement
This Non-Exclusive Patent License Agreement (this “Agreement”) is by and between Icahn School of Medicine at Mount Sinai, a New York not-for-profit education corporation, with a principal place of business at One Gustave L. Levy Place, New York, NY 10029 (“Mount Sinai”) and Mount Sinai Genomics, Inc., a Delaware corporation with a principal place of business at 1425 Madison Avenue, New York, NY 10029 (“MSGI”). This Agreement will become effective on June 1, 2017, (the “Effective Date”). Mount Sinai and MSGI are individually referred to herein as a “Party” and together as the “Parties”.
WHEREAS, Mount Sinai is a center for patient care, research and education and the owner of certain intellectual property relating to diagnosis, prognosis, or identification of humans with disorders, conditions or diseases, whether quantitative or qualitative, or both;
WHEREAS, MSGI is interested in [***] and wishes to obtain from Mount Sinai certain rights to such intellectual property and [***]; and
WHEREAS, Mount Sinai has determined that the [***] subject to the terms and conditions of this Agreement is in the best interest of Mount Sinai, consistent with Mount Sinai’s educational and research missions and goals.
NOW THEREFORE, in consideration of the mutual rights and obligations contained in this Agreement, and intending to be legally bound, the Parties hereby agree as follows:
1.    DEFINITIONS
1.1    “Affiliate” means any Entity that Controls, is Controlled by, or is under common Control with MSGI, directly or indirectly. Without limiting the generality of the foregoing, MSGI will be deemed to Control another Entity if MSGI owns or directly or indirectly Controls more than fifty percent (50%) of the voting stock or other securities of such Entity. For clarity, Mount Sinai shall not be considered an Affiliate of MSGI for purposes of this Agreement.
1.2    “Business Day” means a day other than Saturday, Sunday, or any day on which commercial banks located in New York, New York are authorized or obligated by law to close.
1.3    “Calendar Year” means January 1 through December 31 of a given year.
1.4    “Change of Control” means a change in Mount Sinai’s Control of MSGI. Among other circumstances, a Change of Control event shall be deemed to have occurred if and when Mount Sinai’s ownership interest in MSGI decreases to less than 51% of the total outstanding shares of Sponsor’s voting securities.
1.5    “Commercial Sale” means any bona fide transaction with a Third Party for which consideration is received or expected for the sale, use, lease, transfer or other disposition of a Licensed Product, and a Commercial Sale is deemed completed at the time that MSGI, its Affiliate or Sublicensee invoices, ships or receives payment for a Licensed Product, whichever occurs first.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	1

CONFIDENTIAL

1.6    “Commercialization” means activities directed to obtaining pricing and reimbursement approvals, marketing, promoting, distributing, importing, exporting, using, offering for sale or lease, selling or leasing a product or service anywhere in the world. When used as a verb, “Commercialize” means to engage in Commercialization.
1.7    “Confidential Information” shall have the meaning assigned in Section 5.
1.8    “Control” means an event whereby the power to direct the management and policies of an Entity, directly or indirectly, whether through the ownership of voting securities, by contract, or otherwise, and the terms “Controlling” and “Controlled” have correlative meanings.
1.9    “Development” means [***]. When used as a verb, “Develop” means to engage in Development.
1.10    “EMA” means the European Medicines Agency or any successor agency thereto.
1.11    “Entity” means a corporation, an association, a joint venture, a partnership, a trust, a business, an institution, an individual, a government or political subdivision thereof, including an agency, or any other organization that can exercise independent legal standing.
1.12    “Exploit” means, [***]. “Exploitation” has a correlative meaning.
1.13    “FDA” means the United States Food and Drug Administration or any successor agency thereto.
1.14    “Field of Use” means [***], whether [***] or [***], or both. For avoidance of doubt, Field of Use shall not include [***].
1.15    “First Commercial Sale” means, on a country-by-country basis, the first time a Commercial Sale is made by or on behalf of MSGI, its Affiliates, or Sublicensees.
1.16    “Health Care Law” means all applicable laws with respect to matters primarily relating to patient care and human health and safety, including where appropriate such laws pertaining to: (i) the research, testing, production, manufacturing, marketing, transfer, distribution and sale of drugs, devices, and biologics, including, without limitation, the United States Food, Drug and Cosmetic Act and the regulations promulgated thereunder and equivalent applicable laws of other governmental authorities; (ii) the reimbursement and payment for health care products and services, including any United States federal health care program (as such term is defined in 42 U.S.C. § 1320a-7b(f)), and programs and arrangements pertaining to providers of health care products or services that are paid for by any governmental authority or other Entity, including the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. § 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), 42 U.S.C. § 1320a-7 and 1320a-7a and the regulations promulgated pursuant to such statutes, Medicare (Title XVIII of the Social Security Act) and the regulations promulgated thereunder, Medicaid (Title XIX of the Social Security Act) and the regulations promulgated thereunder, and equivalent applicable laws of other governmental authorities; and (iii) the privacy and security of patient-identifying health care information, including, without limitation, the Health Insurance 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	2

CONFIDENTIAL

Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.) and the regulations promulgated thereunder and equivalent applicable laws of other governmental authorities; in each of the foregoing (i) through (iii), as such laws may be amended from time to time.
1.17    “Infringement Action” means any threatened or pending action, claim, litigation, or proceeding (other than oppositions, cancellations, interferences, reissue proceedings, or reexaminations), respecting any Licensed Patent.
1.18    “Licensed Patents” means the Patents listed on Exhibit A hereto, which is hereby incorporated into and made part of this Agreement.
1.19    “Licensed Product” means any product or service or component of any of the foregoing, the Development, Manufacturing, Commercialization, use, rental or lease of which would, in the absence of the licenses granted to MSGI hereunder, infringe at least one Valid Claim.
1.20    “Licensed Product Data” means [***] directly relating to [***].
1.21    “Licensed Process” means any method or process (including, for clarity, any software or algorithm) the use of which, in the absence of the license agreement, would infringe at least one Valid Claim, or employs a Licensed Product.
1.22    “Manufacturing” means all activities directed to sourcing of necessary raw materials, producing, processing quality assurance testing and release of a Licensed Product or Licensed Process including but not limited to reagents, buffers, cleaners and other disposables, and hardware and software components. When used as a verb, “Manufacture” means to engage in Manufacturing.
1.23    “Patent” means: (a) the United States and foreign patents and/or patent applications; (b) any and all patents issuing from the foregoing; (c) any and all claims of continuation-in-part applications that claim priority to the United States patent applications, but only where such claims are directed to inventions disclosed in the manner provided in the first paragraph of 35 U.S.C. § 112 in such United States patent applications, and such claims in any patents issuing from such continuation-in-part applications; (d) any and all foreign patent applications, foreign patents, or related foreign patent documents that claim priority to the patents and/or patent applications; and (e) any and all divisionals, continuations, reissues, re-examinations, renewals, substitutions, and extensions of the foregoing.
1.24    “Prosecution” means the filing, preparation, prosecution (including any interferences, reissue proceedings, reexaminations, and oppositions), extension, term adjustment, and maintenance of Licensed Patents. When used as a verb, “Prosecute” means to engage in Prosecution.
1.25    “Quarter” means each three-month period beginning on January 1, April 1, July 1 and October 1 of each Calendar Year; provided, however, that as it relates to the Commercial Sale of Licensed Products, the first Quarter shall be comprised of the time period beginning on the date of First Commercial Sale and ending at the end of the Quarter during which such First Commercial Sale occurs. “Quarterly” means once during each Quarter.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	3

CONFIDENTIAL

1.26    “Quarterly Reports” shall have the meaning assigned in Section 4.
1.27    “Regulatory Approval” means all approvals from the relevant Regulatory Authorities necessary to market a Licensed Product in a country (not including any applicable pricing and governmental reimbursement approvals unless legally required to market the Licensed Product in a country).
1.28    “Regulatory Authority” means any applicable government regulatory authority involved in granting approvals for the marketing of a Licensed Product in any country, including the FDA, EMA, and any corresponding national or regional regulatory authorities.
1.29    “Royalty Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period from the First Commercial Sale of such Licensed Product in such country until expiration of the last Valid Claim of a Licensed Patent covering such Licensed Product in such country.
1.30    “Sublicensee” means any Entity that enters into an agreement or arrangement with MSGI, or receives from MSGI a license grant or option for license grant under the Licensed Patents, to exercise any of the rights granted to MSGI by Mount Sinai hereunder (such agreement, arrangement, or license herein referred to as a “Sublicense”), including to Manufacture, have Manufactured, Commercialize, have Commercialized, or otherwise Exploit a Licensed Product, subject to the then-current applicable article, item, service, technology, and technical data-specific requirements of the U.S. export laws and regulations.
1.31    “Sublicense Income” means consideration MSGI receives, directly or indirectly, from any Sublicensee or other Third Party in consideration of a Sublicense or otherwise in consideration of any of the rights granted to MSGI under this Agreement (including any option or contingent right to obtain a sublicense or other right), that is not an earned royalty a portion of which will be payable to Mount Sinai as provided in Section 3.4, including but not limited to any fixed fee, option fee, license fee, maintenance fee, milestone payment, unearned portion of any minimum royalty payment, equity, joint marketing fee, intellectual property cross license, settlement agreement, research and development funding in excess of MSGI’s cost of performing such research and development, and any other property, consideration or thing of value given or exchanged for a sublicense or otherwise in consideration of any of the rights granted to Licensee under this Agreement, regardless of how MSGI and Sublicensee characterize such payments or consideration. Any earned royalty received by MSGI from a Sublicensee that is greater than the appropriate royalty listed in Section 3.3 hereunder will be considered Sublicense Income.
1.32    “Term” means the term of this Agreement which will commence on the Effective Date and expire upon the expiration of the last Royalty Term for the last Licensed Product and/or Licensed Process, unless terminated earlier pursuant to Section 10.
1.33    “Territory” See attached Exhibit A.
1.34    “Third Party” means any Entity other than a Party or its Affiliates.
1.35    “Valid Claim” means: (a) an unexpired claim of an issued Patent within the Licensed Patents that has not been ruled unpatentable, invalid or unenforceable by a final and 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	4

CONFIDENTIAL

unappealable decision of a court or other competent authority in the subject country; or (b) a pending claim of a Patent application within the Licensed Patents which has been prosecuted in good faith and has not been pending for more than [***] years from the first substantive office action.
2.    LICENSE GRANT
2.1    Non-Exclusive License. Subject to the terms and conditions set forth herein, Mount Sinai hereby grants to MSGI a royalty-bearing, non-exclusive, non-transferable license under the Licensed Patents to Exploit Licensed Products and/or Licensed Processes in the Field of Use, during the Term and throughout the Territory.
2.2    Sublicensing. Subject to the terms and conditions set forth herein, Mount Sinai hereby grants to MSGI the right to grant Sublicenses, provided that any and all such Sublicenses shall:
a.    obligate the Sublicensee to abide by and be subject to all of the terms, conditions, and limitations of this Agreement (including all exhibits and schedules hereto) applicable to MSGI;
b.    expressly prohibit the Sublicensee from granting further sublicenses and declare any such purported grant of a further sublicense to be invalid and unenforceable;
c.    cause the Sublicensee to comply with the applicable provisions of this Agreement to the same extent as MSGI is required to comply and include a provision providing for the termination of the Sublicense, upon written request by Mount Sinai, in the event that the Sublicensee does not so comply;
d.    provide that, in the event of any inconsistency between the Sublicense and this Agreement, this Agreement shall control;
e.    obligate the Sublicensee to submit annual, Quarterly, and interim reports to Mount Sinai, consistent with the reporting provisions of Article 4 and all other relevant provisions herein; and
f.    be written in the English language (for clarity, this is a reference to the original Sublicense as executed; provision of a translation to Mount Sinai shall not satisfy this requirement).
2.3    If MSGI enters into any agreement, arrangement, or license purporting to grant rights to any Licensed Patents that does not comport with the requirements of Section 2.2, or is otherwise inconsistent with the terms and conditions of this Agreement, such agreement, arrangement, or license shall be null and void. MSGI acknowledges and agrees that entering into such an agreement, arrangement, or license constitutes a material breach of this Agreement.
2.4    MSGI shall notify Mount Sinai of any proposed grant of a Sublicense and provide to Mount Sinai a copy of any proposed Sublicense at least forty (40) Business Days prior to execution thereof for review and comment by Mount Sinai, and MSGI will not enter into such Sublicense without incorporating such comments, to the extent such comments are reasonable.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	5

CONFIDENTIAL

2.5    MSGI hereby agrees to remain fully liable under this Agreement to Mount Sinai for the performance or non-performance under this Agreement and the relevant Sublicense by any party to those agreements. MSGI shall enforce all such Sublicenses against its Sublicensees, ensuring its Sublicensees’ performance in accordance with the terms of this Agreement and the relevant Sublicense. No such Sublicense or attempt to obtain a Sublicense shall relieve MSGI of its obligations hereunder to pay to Mount Sinai any and all license fees, royalties and other payments due under the Agreement.
2.6    Government Rights. All rights and licenses granted by Mount Sinai to MSGI under this Agreement are subject to: (a) any limitations imposed by the terms of any government grant, government contract or government cooperative agreement applicable to the technology that is the subject of this Agreement, and (b) applicable requirements of 35 U.S.C. § 200 et seq., as amended, and implementing regulations and policies. Without limitation of the foregoing, MSGI agrees that, to the extent required under 35 U.S.C. § 204, any Licensed Product used, sold, distributed, rented or leased by MSGI, its Affiliates, or Sublicensees in the United States will be Manufactured substantially in the United States. In addition, MSGI agrees that, to the extent required by law or regulation including under 35 U.S.C. § 202(c)(4), the United States government is granted a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any Licensed Patent throughout the world.
2.7    No Implied Licenses. Except as expressly provided under this Article 2, no right or license is granted under this Agreement (expressly or by implication or estoppel) by Mount Sinai to MSGI, its Affiliates, or Sublicensees under any tangible or intellectual property, materials, Patent, Patent application, trademark, copyright, technical information, data, or other proprietary right.
3.    FEES, ROYALTIES, AND PAYMENTS
3.1    License Maintenance Fee. As additional consideration for the license and other rights granted under this Agreement, starting on the date of a Change of Control and at each anniversary of such date thereafter, MSGI shall pay to Mount Sinai an annual, non-refundable, non-creditable license maintenance fee, payable through the expiration of the Royalty Term, according to the following schedule, provided that the Parties agree to negotiate in good faith a reduction of such annual fee in the event that this Agreement is terminated or amended as to any specified Licensed Patent:
						
	YEAR	ANNUAL FEE
	Each year until the expiration of the Royalty Term	[***] U.S. Dollars ($[***] USD)

3.2    Running Royalties. As additional consideration for the license and other rights granted under this Agreement, during the Royalty Term, MSGI shall pay to Mount Sinai running royalties as specified in Exhibit C; provided that, upon a Change of Control event, MSGI shall pay running royalties solely in accordance with section a of Exhibit C hereto, and section b of Exhibit C hereto shall no longer have any effect.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	6

CONFIDENTIAL

3.3    Sublicense Fees. MSGI shall pay Mount Sinai [***] of all Sublicense Income within [***] days after receipt of such Sublicense Income. All consideration received by MSGI from any Sublicensee shall be fully auditable by Mount Sinai pursuant to the audit right in Section 4.9. MSGI shall not receive from any Sublicensee anything of value in lieu of cash payments inconsideration for any Sublicense without the express prior written consent of Mount Sinai. Any non-cash consideration, including, without limitation, equity in other companies or equity investments in MSGI, received by MSGI from any Sublicensee will be valued at its fair market value as of the date of receipt by MSGI for purposes of calculating Sublicense Income. MSGI shall not sell or transfer, voluntarily or involuntarily, to a Third Party any of MSGI’s interest in any portion of any future sublicensing revenues under any Sublicense without the prior written consent of Mount Sinai.
4.    REPORTS AND PAYMENTS
4.1    Reporting of First Commercial Sale. In addition to the Quarterly Reports required under Section 4.2 below, MSGI shall provide a written report to Mount Sinai setting forth the date of First Commercial Sale in each country within sixty (60) days of the occurrence thereof. All reports set forth in this Section 4, including Quarterly Reports and Annual Progress Reports, shall be considered the Confidential Information of MSGI.
4.2    Quarterly Royalty Report. Within sixty (60) days after the Quarter in which any First Commercial Sale occurs, and within sixty (60) days after each Quarter thereafter, MSGI shall provide Mount Sinai with a written report detailing the number and type of test (including a test for one or more conditions) by MSGI that is covered by one or more Valid Claims during such Quarter and the royalty payments due to Mount Sinai for such Quarter pursuant to Article 4 (each such report, a “Quarterly Report”). Each Quarterly Report shall include at least the following:
a.    the number and type of test (including a test for one or more conditions) by MSGI that is covered by one or more Valid Claims;
b.    total royalty payments due to Mount Sinai by Licensed Product and by country;
c.    names and addresses of all Sublicensees, all revenue received by MSGI from such Sublicensees and all amounts payable, as applicable; and
4.3    Each Quarterly Report shall be in substantially similar form as Exhibit B attached hereto (which is hereby incorporated into and made a part of this Agreement), or to such other form as Mount Sinai may provide from time to time. Each Quarterly Report shall be certified as true and correct by an officer of MSGI. With each Quarterly Report submitted, MSGI shall pay to Mount Sinai the royalties and fees due and payable under this Agreement, to the extent not already paid pursuant to Article 4. If no royalties or fees are due and payable, MSGI shall so report. MSGI’s failure to timely submit to Mount Sinai a Quarterly Report substantially in the required form will constitute a material breach of this Agreement, and, if such breach is not remedied within ten (10) days’ written notice from Mount Sinai, Mount Sinai may terminate this Agreement in full pursuant to Section 10 hereof. MSGI will continue to deliver Quarterly 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	7

CONFIDENTIAL

Reports to Mount Sinai after the termination or expiration of this Agreement with respect to any Quarter during which this Agreement remained in effect and until such time as all Licensed Product(s) permitted to be sold after termination have been sold or destroyed.
4.4    Annual Progress Report. On the first Business Day of each Calendar Year following the Effective Date, MSGI shall submit to Mount Sinai a written report covering MSGI’s, its Affiliate’s and/or Sublicensees’, as applicable, progress (if any) in: (i) Developing and Commercializing Licensed Products and/or Licensed Processes; (ii) research and Development activities, including status and plans for obtaining any necessary governmental approvals or CPT codes, performed during the past year, and the plans for research and Development activities for the following year; and (iii) marketing activities for the past year and planned for the next year, and MSGI’s internal sales estimate for the following year (an “Annual Progress Report”). Each Annual Progress Report shall be in substantially similar form and contain at least the information required by Exhibit C attached hereto (which is hereby incorporated into and made a part of this Agreement), or in such other form as may be provided by Mount Sinai from time to time.
4.5    Annual Sublicense Reports. On the first Business Day of each Calendar Year following the Effective Date, MSGI shall submit to Mount Sinai a written report setting forth: (a) the names and addresses of all Sublicensees, (b) all Sublicense revenue received by MSGI from each Sublicensee during the preceding Calendar Year, and (c) all amounts payable or paid to Mount Sinai under Section 3 during the preceding Calendar Year. In addition, within fifteen (15) days of MSGI’s receipt of any Sublicense revenue, MSGI shall submit to Mount Sinai the amount payable to Mount Sinai under Section 3, together with a written report describing the triggering event, the gross amount of Sublicense revenue received, any applicable fees, credits or deductions, and the net amount of Sublicense revenue payable to Mount Sinai. After any First Commercial Sale has occurred, MSGI’s obligation to provide such annual sublicense reports shall be satisfied by providing Quarterly Reports pursuant to Section 4.
4.6    Payment and Currency. All dollar amounts referred to in this Agreement are expressed in United States Dollars and MSGI shall make all payments due to Mount Sinai in U.S. Dollars, without deduction of exchange, collection, wiring fees, bank fees, or any other charges, within thirty (30) days following the Quarter. Each payment will reference Agreement AGR-11352. All payments to Mount Sinai will be made in U.S. Dollars by wire transfer or check payable to the Icahn School of Medicine at Mount Sinai and sent to:
						
	By Electronic Transfer:
Icahn School of Medicine at Mount Sinai
Mount Sinai Bank Account Number: [***]
Routing ABA Number: [***]
Mount Sinai Ref:
[***]
	By Check:
Mount Sinai Innovation Partners
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place Box 1675
New York, NY 10029

4.7    [INTENTIONALLY LEFT BLANK]
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	8

CONFIDENTIAL

4.8    Late Payments. In the event undisputed royalty payments or other fees are not received by Mount Sinai when due hereunder, MSGI shall pay to Mount Sinai interest charges that will accrue interest from the date due until paid at a rate equal to [***] per month (or the maximum allowed by law, if less).
4.9    Records and Audit Rights.
a.    MSGI shall keep, and cause its Affiliates and Sublicensees to keep, complete, true and accurate records and books containing all particulars that may be necessary for the purpose of showing the amounts payable to Mount Sinai hereunder. Records and books shall be kept at MSGI’s principal place of business or the principal place of business of the appropriate division of MSGI to which this Agreement relates. The records for each Quarter will be maintained for at least five (5) years after submission of the applicable report. Such books and the supporting data shall be open to inspection by Mount Sinai, its contractors or agents, upon at least thirty (30) days prior notice to MSGI, its Affiliate, or Sublicensee, as applicable, at all reasonable terms for a term of five (5) years following the end of the Calendar Year to which they pertain, for the purpose of verifying MSGI’s royalty statement or compliance in other respects with this Agreement. Such access will be available to Mount Sinai on at least 45 days’ advance notice to MSGI, its Affiliate, or Sublicensee, as applicable, no more than one audit of MSGI and each Affiliate, or Sublicensee shall be conducted in any 2 calendar years, during normal business hours, and once in any 2 calendar years for five (5) years after the expiration or termination of this Agreement. If any amounts due to Mount Sinai have been underpaid, then MSGI shall promptly pay to Mount Sinai the amount of such underpayment plus accrued interest of LIBOR plus 2% but never greater than 8% (or maximum allowed by law, if less). Should such inspection lead to the discovery of at least a [***] percent ([***]%) or [***] Dollar ($[***]) discrepancy in reporting to Mount Sinai’s detriment (whichever is greater), MSGI agrees to reimburse Mount Sinai for the full cost of such inspection. Whenever MSGI, its Affiliate, or Sublicensee has its books and records audited by an independent certified public accountant, MSGI, its Affiliate, or Sublicensee, as applicable, will, within thirty (30) days of the conclusion of such audit, provide Mount Sinai with a written statement, certified by said auditor, setting forth the calculation of royalties, fees, and other payments due to Mount Sinai over the time period audited as determined from the books and records of such party.
b.    Such audits may, in Mount Sinai’s sole discretion, consist of a self-audit conducted by MSGI at MSGI’s expense and certified in writing by a certified public accountant. All information examined pursuant to this Agreement shall be deemed to be the Confidential Information of MSGI. Further, whenever MSGI and/or its affiliates has its books and records 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	9

CONFIDENTIAL

audited by an independent certified public accountant, MSGI and/or its affiliates will, within 30 days of the conclusion of such audit, provide Mount Sinai with a written statement of said auditor, setting forth the calculation of amounts due to Mount Sinai over the time period audited, as determined from the books and records of MSGI, but said auditor does not need to give any audit opinion with said statement.
5.    CONFIDENTIALITY; PUBLICITY; USE OF NAME
5.1    “Confidential Information” means any and all information of a Party (the “Disclosing Party”), or such information of Affiliates or Third Parties provided on behalf of such Party to the other Party (“Receiving Party”), that is disclosed in tangible form marked as “confidential” upon disclosure or, if disclosed in oral or other intangible form, is identified as confidential at the time of disclosure and summarized in a writing that is marked as “confidential” and provided to the Receiving Party within thirty (30) days of the intangible disclosure, provided however that failure to so mark or summarize shall not alter the confidential nature of such Confidential Information if a reasonable person would, based on the content and/or context of the disclosure, recognize such disclosure was intended as confidential. Notwithstanding the foregoing, Confidential Information shall not include information that: (i) is available to the public at the time of disclosure or, after disclosure, becomes a part of the public domain by publication or otherwise, through no fault of the Receiving Party; (ii) is already properly possessed by the Receiving Party prior to receipt from the Disclosing Party; (iii) was received by the Receiving Party without obligation of confidentiality or limitation on use from a Third Party who had the lawful right to disclose such information; or (iv) was independently developed by or for the Receiving Party by any person or persons who had no knowledge or benefit of the Disclosing Party’s Confidential Information, as demonstrated by the Receiving Party’s written or electronic records created contemporaneously with such independent development.
5.2    Confidentiality. The Receiving Party shall maintain in confidence and not disclose to any Third Party any Disclosing Party’s Confidential Information, using the same degree of care it uses to protect its own confidential information of a similar nature but in no event using less than a reasonable degree of care. The Receiving Party will use Disclosing Party’s Confidential Information solely as required to undertake its rights and obligations under this Agreement. The Receiving Party will ensure that its employees, independent contractors, Affiliates, and Sublicensees (“Recipient Individuals”) have access to Disclosing Party’s Confidential Information only on a need to know basis, are informed of all the obligations attaching to such Confidential Information in advance of being given access to it, and are required to comply with such Receiving Party’s obligations under this Agreement. Receiving Party shall be fully responsible to Disclosing Party for such compliance by its Recipient Individuals. Notwithstanding the foregoing, the Receiving Party may disclose Disclosing Party’s Confidential Information to the limited extent required by law, court order, or other governmental authority with jurisdiction provided that the Receiving Party: (a) promptly provides the Disclosing Party, to the extent legally permissible, with written notice of such requirement, (b) uses reasonable efforts to obtain confidential treatment of such Disclosing Party’s Confidential Information by such court or governmental authority, and (c) cooperates, at 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	10

CONFIDENTIAL

the Disclosing Party’s written request and expense, with the Disclosing Party’s legal efforts to prevent or limit the scope of such required disclosure; the Receiving Party shall in all other respects continue to hold such Confidential Information as confidential and subject to all obligations of this Article 6. The Receiving Party’s obligations of confidentiality and non-use restrictions as set forth in this Article 6 shall be for a period of five (5) years from receipt of the Confidential Information from the Disclosing Party.
5.3    Publicity. The Parties may issue a press release upon mutual written agreement and, if so, will cooperate to determine the timing and content of such press release. All press releases shall be subject to the terms and conditions of this Agreement, including Sections 5.2 and 5.4.
5.4    Use of Mount Sinai’s Name. MSGI and its Affiliates, Sublicensees, employees and agents may not use the name, logo, seal, trademark, or service mark of Mount Sinai or any school, organization, employee, student or representative of Mount Sinai (or any adaptation of any of the foregoing) without the prior written consent of Mount Sinai, which consent will be granted or denied by the Vice President of the Office of Marketing and Communications of the Mount Sinai Health System (in his or her sole discretion).
6.    PATENT MATTERS
6.1    Patent Prosecution. Mount Sinai shall control the Prosecution of Licensed Patents and the selection of patent counsel. MSGI and Mount Sinai shall reasonably consult each other regarding such management, and MSGI shall have the right to provide input and guidance to Mount Sinai relating to ongoing prosecution matters relating to the Licensed Patents. It is agreed and understood, however, the Mount Sinai shall have the ultimate decision making authority (in its sole discretion) with respect to Licensed Patent Prosecution matters.
6.2    Infringement. In the event that MSGI becomes aware of any suspected infringement of any Licensed Patent or any Infringement Action, MSGI shall promptly notify Mount Sinai thereof. At its sole expense, Mount Sinai will have sole and full authority with respect to such infringement matters (whether through litigation, settlement negotiation, mediation, or other means) and shall retain all recoveries therefrom. MSGI shall cooperate with Mount Sinai’s requests to the extent reasonably possible, including joining the Infringement Action if requested by Mount Sinai.
7.    REPRESENTATIONS; DISCLAIMER OF WARRANTIES;
LIMITATION OF LIABILITIES
7.1    Each Party represents to the other Party that: (a) as of the Effective Date it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder, and (b) this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	11

CONFIDENTIAL

7.2    Health Care Law. Each Party agrees that from the Effective Date and throughout the Term of this Agreement that it (and its agents and employees involved in the performance of this Agreement) shall not, and it shall use reasonable efforts to cause its Affiliates and each of its vendors, suppliers and subcontractors involved in the performance of this Agreement, not to be debarred, excluded or disqualified by any Regulatory Authority or other governmental entity pursuant to 21 U.S.C. § 335a or any other Health Care Law. Each Party shall notify the other Party in writing immediately if any such debarment, exclusion or disqualification occurs or comes to its attention, and shall, with respect to any Entity so debarred promptly remove such Entity from performing this Agreement.
7.3    DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITIES. THE LICENSED PATENTS, MATERIALS, TECHNICAL INFORMATION, LICENSED PRODUCTS, LICENSED PROCESSES, AND ANY OTHER TECHNOLOGY OR INFORMATION PROVIDED OR LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. MOUNT SINAI MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON INFRINGEMENT OR TITLE WITH RESPECT THERETO. MOUNT SINAI WILL NOT BE LIABLE TO MSGI, ITS SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM ARISING FROM OR ATTRIBUTABLE TO MSGI’S USE OF THE LICENSED PATENTS, MATERIALS, TECHNICAL INFORMATION, LICENSED PRODUCTS, AND ANY OTHER TECHNOLOGY OR INFORMATION PROVIDED OR LICENSED UNDER THIS AGREEMENT, OR ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS. NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY, OR ITS SUCCESSORS OR ASSIGNS, OR TO ANY THIRD PARTY, FOR LOST PROFITS, BUSINESS INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL OR OTHER DAMAGES OF ANY KIND.
7.4    Disclaimer of Specific Warranties. Without limiting the generality of the foregoing, nothing in this Agreement shall be construed as:
a.    a warranty or representation by Mount Sinai as to the validity or scope of any Licensed Patents;
b.    a warranty or representation by Mount Sinai that anything made, used, sold, distributed, or as applicable publicly performed, publicly displayed, derived from, or otherwise disposed of pursuant to any license granted under this Agreement is or will be free from infringement of intellectual property rights of third parties;
c.    an obligation by Mount Sinai to bring or prosecute actions or suits against third parties for infringement, misappropriation, or other similar causes of action related to the Licensed Patents, except as expressly provided in this Agreement; or
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	12

CONFIDENTIAL

d.    conferring by implication, estoppel or otherwise any license or rights under any intellectual property rights of Mount Sinai other than Licensed Patents, as and to the extent expressly set forth herein.
7.5    Limitation of Liability. Notwithstanding any provision in this Agreement to the contrary, Mount Sinai’s aggregate liability under this Agreement shall not exceed an amount equal to the maximum amount of all payments made by MSGI to Mount Sinai pursuant to Article 3 hereof during the full Calendar Year during which MSGI paid to Mount Sinai the highest aggregate amount pursuant to that Article 3.
8.    INDEMNIFICATION
8.1    Indemnification. MSGI will defend, indemnify and hold harmless Mount Sinai, and its trustees, officers, faculty, agents, employees and students (each, an “Indemnified Party”) from and against any and all claims, actions, liabilities, losses, damages, judgments, costs or expenses suffered or incurred by the Indemnified Parties, including attorneys’ fees and related costs (collectively, “Liabilities”), caused in whole or in part by:
a.    any [***] of MSGI, its Affiliates or Sublicensees, or of any of the officers, directors, employees or agents of any of the foregoing, in connection with [***], and/or
b.    the enforcement of this Article by any Indemnified Party;
except in each case to the extent such Liabilities result solely from the [***] of an Indemnified Party. For clarity, Liabilities under this Section include, but are not limited to, Liabilities arising out of, resulting from, or caused by: (i) the [***] by MSGI or its Sublicensees, Affiliates, assignees, vendors or Third Parties; or (ii) a failure to perform under this Agreement or any Sublicense [***], or (iii) a claim (excluding claims based on [***]) by [***], or [***]; or (iv) [***] of MSGI, its Affiliates, Sublicensees, assignees, vendors or associated Third Parties relating to [***], such as claims by or on behalf of a [***].
8.2    Indemnification Procedure. An Indemnified Party will promptly provide MSGI with written notice of any Liability that is indemnifiable under this Article; provided, however, that the failure to so notify shall not relieve MSGI of its indemnification obligations hereunder except to the extent of any material prejudice to MSGI as a direct result of such failure. Provided that MSGI can demonstrate sufficient financial and legal resources, MSGI shall control such defense and all negotiations relative to the settlement of any indemnifiable claim or action, except that MSGI shall not settle or compromise any claim or action in any manner that may impose restrictions or obligations on any Indemnified Party, or that grants any rights to the Licensed Patents or Licensed Products, without Mount Sinai’s prior written consent. If MSGI fails or declines to assume the defense against any claim or action within thirty (30) days after notice thereof, then Mount Sinai may assume and control the defense of such claim or action for the account and at the risk of MSGI, and any Liabilities related to such claim or action will be conclusively deemed a liability of MSGI. The indemnification rights of the Indemnified Parties under this Article 0 are in addition to all other rights that an Indemnified Party may have at law, in equity or otherwise.
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	13

CONFIDENTIAL

9.    INSURANCE
9.1    Coverages. MSGI will procure and maintain appropriate insurance policies for the following coverages with respect to personal injury, bodily injury, property damage or contractual liability arising out of MSGI’s performance under this Agreement as follows: (a) during the Term, comprehensive general liability, including broad form and contractual liability, in a minimum amount of $[***] per claim and $[***] in the annual aggregate; and (b) prior to the sale of the first Licensed Product, product or professional liability coverage, as applicable, in a minimum amount of $[***] per claim and $[***] in the annual aggregate. Mount Sinai may review periodically the adequacy of the minimum amounts of insurance for each type of coverage required by this Article 9, and Mount Sinai reserves the right to reasonably require MSGI to adjust the limits accordingly. The required minimum amounts of insurance do not constitute a limitation on MSGI’s liability or indemnification obligations to Mount Sinai under this Agreement.
9.2    Other Requirements. Any policies of insurance required by Section 9.1 above will be issued by an insurance carrier with an A.M. Best rating of “A” or better and will name Mount Sinai as an additional insured, on a primary and non-contributory basis, with respect to MSGI’s performance under this Agreement. MSGI will provide Mount Sinai with insurance certificates evidencing the required coverage within thirty (30) days after the commencement of each policy period and any renewal periods. Each certificate will provide that the insurance carrier will notify Mount Sinai in writing at least thirty (30) days prior to the cancellation or material change in coverage.
10.    TERM AND TERMINATION
10.1    Expiration of Royalty Term. Upon expiration of the Royalty Term with respect to a Licensed Product in any country and payment in full of all amounts owed hereunder with respect to such Licensed Product in such country, MSGI will have a non-exclusive, fully paid license for such Licensed Product in such country.
10.2    Termination by Mount Sinai. If MSGI should: (i) [***] (including if MSGI should [***]); (ii) seek voluntary bankruptcy protection, or have an involuntary bankruptcy action filed against it that is not dismissed within sixty (60) days; or (iii) enter into a composition with creditors, or have a receiver appointed for it; then Mount Sinai may give written notice of such default to MSGI. If MSGI should fail to cure such default within sixty (60) days of such notice, the rights, privileges, and license granted hereunder shall automatically terminate.
10.3    Termination by MSGI. MSGI may terminate this Agreement, in whole or as to any specified Licensed Patent, at [***], by giving written notice thereof to Mount Sinai. Such termination shall be effective ninety (90) days after such notice and all of MSGI’s rights associated therewith shall cease as of that date.
10.4    Cessation of [***]. If MSGI shall cease to [***], this Agreement shall terminate upon thirty (30) days written notice by Mount Sinai.
10.5    Challenge of Patents. MSGI agrees that nothing herein shall be construed as preventing it from challenging the validity or enforceability of the Licensed Patents, at any time. 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	14

CONFIDENTIAL

In the event that MSGI shall, however, challenge the validity or enforceability of any of the Licensed Patents, or otherwise indicate the payment of any royalty due under this Agreement is made under protest, MSGI agrees that Mount Sinai shall have the right, but not the obligation, to terminate this Agreement immediately upon providing written notice of the same to MSGI.
11.    EFFECT OF TERMINATION
11.1    Continuing Obligations. Any termination pursuant to Section 10 hereof shall not relieve MSGI of any monetary obligation or any other obligation or liability accrued hereunder, nor shall it rescind or give rise to any right to rescind any payments made or other consideration given to Mount Sinai hereunder prior to the time such termination becomes effective. Such termination shall not affect in any manner any rights of Mount Sinai arising under this Agreement prior to the date of such termination. MSGI shall pay all attorneys’ fees and costs incurred by Mount Sinai in enforcing any obligation of MSGI or accrued right of Mount Sinai
11.2    Survival of Terms. In addition to any provision which by its terms contemplates performance after the Term, the following provisions shall survive the expiration or termination of this Agreement: Articles 1 (Definitions), 3 (Fees, Royalties, Milestones, and Payments), 4.9 (Records and Audit Rights), 5 (Confidentiality; Publicity; Use of Name), 7 (Representations; Disclaimer of Warranties; Limitation of Liabilities), 8 (Indemnification), 9 (Insurance), 11 (Effect of Termination), and 12 (Additional Provisions).
11.3    Licensed Product on Hand. Upon expiration or termination of this Agreement by either Party, MSGI shall provide Mount Sinai with a written inventory of all Licensed Products in process of manufacture, in use, or in stock. MSGI may dispose of any such Licensed Products within the ninety (90) day period following such expiration or termination; provided, however, that MSGI shall pay royalties and render reports to Mount Sinai thereon in the manner specified herein.
12.    ADDITIONAL PROVISIONS
12.1    Independent Contractors. The Parties are independent contractors. Nothing contained in this Agreement is intended to create an agency, partnership or joint venture between the Parties. At no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party.
12.2    Compliance with Laws. MSGI must comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this Agreement. For example, MSGI will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States government and/or written assurances by MSGI that MSGI will not export data or commodities to certain foreign countries without prior approval of the agency. Mount Sinai does not represent that no license is required, or that, if required, the license will issue.
12.3    Marking. MSGI shall, and agrees to require its Affiliates and Sublicensees to, comply with any marking requirements of the intellectual property laws of the applicable countries in the Territory to the extent any failure to do so would materially and adversely affect the Licensed Patents or any Licensed Product, or either Party’s ability to avail itself of all 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	15

CONFIDENTIAL

potential remedies for any infringement of the Licensed Patents, and particularly agrees to permanently and legibly mark all Licensed Products made, used, reproduced, or sold under the terms of this Agreement, or their respective containers, in accordance with the applicable provisions set forth in the Patent marking and notice provisions under Title 35 of the United States Code. Any Sublicense shall impose on the Sublicensee obligations substantially similar to those imposed in this paragraph.
12.4    Modification, Waiver and Remedies. This Agreement may only be modified by a written amendment that is executed by an authorized representative of each Party. Any waiver must be express and in writing. No waiver by either Party of a breach by the other Party will constitute a waiver of any different or succeeding breach. Unless otherwise specified, all remedies are cumulative.
12.5    Assignment. MSGI may not assign this Agreement or any part of it, either directly or by merger or operation of law, without the prior written consent of Mount Sinai. Any such assignment will be valid only if: (a) at least thirty (30) days before the closing of the proposed transaction, MSGI has given Mount Sinai written notice and such background information as may be reasonably necessary to enable Mount Sinai to give an informed consent; and (b) the assignee agrees in writing to be legally bound by this Agreement. Any permitted assignment will not relieve MSGI of responsibility for performance of any obligation of MSGI that has accrued at the time of the assignment. Any assignment granted contrary to this provision will be null and void.
12.6    Notices. Except as otherwise expressly set forth herein, any notice or other required communication under this Agreement (each, a “Notice”) must be in writing, addressed to the Party’s respective Notice Address, and delivered personally or by globally recognized express delivery service, charges prepaid. A Notice will be deemed delivered and received: (a) in the case of personal delivery, on the date of such delivery; and (b) in the case of a globally recognized express delivery service, on the Business Day that receipt by the addressee is confirmed pursuant to the service’s systems. The “Notice Address” of each Party is as follows:
						
	if to Mount Sinai, to:	Icahn School of Medicine at Mount Sinai
Mount Sinai Innovation Partners
One Gustave L. Levy Place, Box 1675
New York, NY 10029
Attention:  Vice President and Executive Director

		
	and a copy of legal notices only to:	One Gustave L. Levy Place, Box 1099, New York, NY 10029
Attention: Office of General Counsel
		
	if to MSGI, to:	Mount Sinai Genomics, Inc.
1425 Madison Avenue
New York, NY 10029
Attention:  General Counsel

12.7    Severability and Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	16

CONFIDENTIAL

this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the Parties’ original intent.
12.8    Headings and Counterparts. The headings of the articles and sections included in this Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in several counterparts, and execution signatures may be exchanged electronically including by facsimile or as scanned e-mail attachments, and signatures so exchanged shall be considered as original for all purposes and taken together will constitute one and the same instrument.
12.9    Governing Law. This Agreement will be governed in accordance with the laws of the State of New York, without giving effect to the conflict of law provisions of any jurisdiction.
12.10    Dispute Resolution. If a dispute arises between the Parties concerning any right or duty under this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute amicably. If the Parties are unable to resolve the dispute amicably, the Parties each hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts located in the County and State of New York.
12.11    Integration. This Agreement, together with all attached Exhibits, contains the entire agreement between the Parties with respect to the Licensed Patents, and supersedes all other oral or written representations, statements, or agreements with respect to such subject matter, including but not limited to, the term sheet exchanged prior to this Agreement.
12.12    Force Majeure. Neither Party will be responsible for nonperformance caused by forces beyond the reasonable control of such Party, including fire, explosion, natural disaster, war (whether declared or not), act of terrorism, strike, or riot, provided that the nonperforming Party uses reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed, and notifies the other Party of such cause as promptly as is reasonably practical given the circumstances.
12.13    Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires: (a) all definitions set forth herein shall be deemed applicable whether the words defined are used herein with initial capital letters in the singular or the plural, (b) the word “will” shall be construed to have the same meaning and effect as the word “shall,” (c) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (d) any reference herein to any Party shall be construed to include the Party’s successors and assigns, (e) the word “notice” shall mean notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (f) provisions that require that a Party or the Parties “agree,” 
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	17

CONFIDENTIAL

“consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (g) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (h) words of any gender include each other gender, (j) words such as “herein,” “hereof” and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (i) the words “include,” “includes” and “including” shall be deemed to be followed by the phrase “but not limited to,” “without limitation,” “inter alia” or words of similar import, and (j) unless “Business Days” is specified, “days” shall mean “calendar days.” In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.
12.14    Business Day Requirements. In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day, then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day.
[Signature Page Follows]
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	18

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.
																		
	MOUNT SINAI GENOMICS, INC.	ICAHN SCHOOL OF MEDICINE
AT MOUNT SINAI
						
	BY:	/s/ Eric Schadt, Ph.D.
	BY:	/s/ Dennis S. Charney, M.D.

						
	NAME:	Eric Schadt, Ph.D.
	NAME:	Dennis S. Charney, M.D.

						
	TITLE:	President and Chief Executive Officer
	TITLE:	Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai

						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	19

Exhibit A
Licensed Patents
[***]
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	20

Exhibit B
Form of Quarterly Royalty Report
Quarterly Royalty and Sublicense Income Report
																														
	Mount Sinai Agreement Number									
	Agreement effective date									
	Time Period of Report									
										
	Licensee royalties									
		Country		Date of First
Sale	Product Name	Royalty rate
utilized	Gross Sales	Deductions	Net Sales	Royalty
		Country A								
		Country B								
		Country C								
										
										
	Sublicense royalties									
				Date of First
Sale	Product Name	Royalty rate
utilized	Gross Sales	Deductions	Net Sales	Royalty
		Sublicensee A Name							
			Country A							
			Country B							
			Country C							
		Sublicensee B Name							
			Country X							
			Country Y							
			Country Z							
										
										
										
	Non-royalty sublicense income	Description of sublicense income triggering event					
							
							
							
		Date of triggering event					
							
							
		Sublicense income gross amount					
							
		Fees, credits, deductions (if applicable)					
							
		Description of fees, credits, deductions (if applicable)					
							
							
							
		Sublicense income net amount					
							
							
	Milestones	Description of milestone triggering event					
							
							
							
		Date of triggering event					
							
							
		Milestone gross amount					
							
		Fees, credits, deductions (if applicable)					
							
		Description of fees, credits, deductions (if applicable)					
							
							
							
		Milestone net amount					

						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	21

Exhibit C
Calculation of Running Royalties
a)    Total Royalties. For Licensed Products or Licensed Processes performed or sold by MSGI, “Total Royalties” shall be determined as follows, on a jurisdiction-by-jurisdiction basis within the Territory: (i) [***] U.S. dollar ($[***]) per [***] (including a [***]) by MSGI that is covered by [***] Valid Claims with respect to the [***], per [***] upon [***], prior to the issuance in the applicable jurisdiction of the first Patent with such a Valid Claim; and (ii) [***] U.S. dollars ($[***]) per [***] (including a [***] conditions) that is covered by one or more Valid Claims with respect to the [***] by MSGI, per [***] upon [***], after the issuance in the applicable jurisdiction of the first Patent with such a Valid Claim.
b)    Royalties Owed by MSGI. For [***] from the Effective Date, or until the date of a Change of Control event, if earlier, in accordance with Section 3.4 above, MSGI shall owe to Mount Sinai, and shall actually remit to Mount Sinai, [***]. For further clarity, starting on the date that the conditions set forth in this subsection (b) are not satisfied, MSGI shall owe to Mount Sinai, and shall actually remit to Mount Sinai, [***]
i)    [***] to [***] in Total Royalties Per Calendar Year. For the first [***] dollars in royalty income in aggregate per calendar year, Mount Sinai’s adjusted royalty distribution rates are as follows: [***]% to inventors, [***]% to the applicable ISMMS department, and [***]% to ISMMS. Accordingly, MSGI shall owe only [***] percent ([***]%) of Total Royalties with respect to the first [***] dollars ($[***]) of Total Royalties in a calendar year. By way of example: if the Total Royalty amount calculated as set forth in subsection (a) above was [***]dollar ($[***]), the actual amount due from MSGI to Mount Sinai hereunder would be calculated as follows: [***].
ii)    Over [***] in Total Royalties Per Calendar Year. For all amounts over [***] dollars in royalty income in aggregate per calendar year, Mount Sinai’s adjusted royalty distribution rates are as follows: [***]% to inventors, [***]% to the applicable ISMMS department, and [***]% to ISMMS. Accordingly, MSGI shall owe only [***] percent ([***]%) of Total Royalties with respect to any portion of Total Royalties in a calendar year that exceeds [***] dollars ($[***]). By way of example: if the Total Royalty amount calculated as set forth in subsection (a) above was [***] and [***] dollar ($[***]), the actual amount due from MSGI to Mount Sinai hereunder with respect to the [***] dollar in excess of [***]dollars (and, for clarity, all dollars thereafter) would be calculated as follows: [***].
						
	Pursuant to SEC Release 34-85381, certain identified information has been excluded from this Exhibit because it is (i) not material and (ii) would be competitively harmful if publicly disclosed. 
	22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]